Пожалуйста, используйте этот идентификатор, чтобы цитировать или ссылаться на этот ресурс: http://elar.urfu.ru/handle/10995/132486
Название: Outcomes of Patients With Hypertrophic Obstructive Cardiomyopathy and Pacemaker Implanted After Alcohol Septal Ablation
Авторы: Veselka, J.
Liebregts, M.
Cooper, R.
Faber, L.
Januska, J.
Kashtanov, M.
Tesarkova, K. H.
Hansen, P. R.
Seggewiss, H.
Shloydo, E.
Popov, K.
Hansvenclova, E.
Bonaventura, J.
Berg, J. T.
Stables, R. H.
Polakova, E.
Дата публикации: 2022
Издатель: Elsevier Inc.
Библиографическое описание: Veselka, J, Liebregts, M, Cooper, R, Faber, L, Januska, J, Kashtanov, M, Tesarkova, KH, Hansen, PR, Seggewiss, H, Shloydo, E, Popov, K, Hansvenclova, E, Bonaventura, J, Berg, JT, Stables, RH & Polakova, E 2022, 'Outcomes of Patients With Hypertrophic Obstructive Cardiomyopathy and Pacemaker Implanted After Alcohol Septal Ablation', JACC: Cardiovascular Interventions, Том. 15, № 19, стр. 1910-1917. https://doi.org/10.1016/j.jcin.2022.06.034
Veselka, J., Liebregts, M., Cooper, R., Faber, L., Januska, J., Kashtanov, M., Tesarkova, K. H., Hansen, P. R., Seggewiss, H., Shloydo, E., Popov, K., Hansvenclova, E., Bonaventura, J., Berg, J. T., Stables, R. H., & Polakova, E. (2022). Outcomes of Patients With Hypertrophic Obstructive Cardiomyopathy and Pacemaker Implanted After Alcohol Septal Ablation. JACC: Cardiovascular Interventions, 15(19), 1910-1917. https://doi.org/10.1016/j.jcin.2022.06.034
Аннотация: Background: Atrioventricular block is a frequent major complication after alcohol septal ablation (ASA). Objectives: The aim of this study was to evaluate the outcomes of patients with implanted permanent pacemaker (PPM) related to a high-grade atrioventricular block after ASA for hypertrophic obstructive cardiomyopathy. Methods: We used a multinational registry (the Euro-ASA registry) to evaluate the outcome of patients with PPM after ASA. Results: A total of 1,814 patients were enrolled and followed up for 5.0 ± 4.3 years (median = 4.0 years). A total of 170 (9.4%) patients underwent PPM implantation during the first 30 days after ASA. Using propensity score matching, 139 pairs (n = 278) constituted the matched PPM and non-PPM groups. Between the matched groups, there were no long-term differences in New York Heart Association functional class (1.5 ± 0.7 vs 1.5 ± 0.9, P = 0.99) and survival (log-rank P = 0.47). Patients in the matched PPM group had lower long-term left ventricular (LV) outflow gradient (12 ± 12 mm Hg vs 17 ± 19 mm Hg, P < 0.01), more pronounced LV outflow gradient decrease (81% ± 17% vs 72% ± 35%, P < 0.01), and lower LV ejection fraction (64% ± 8% vs 66% ± 8%, P = 0.02) and were less likely to undergo reintervention (re-ASA or myectomy) (log-rank P = 0.02). Conclusions: Patients with hypertrophic obstructive cardiomyopathy treated with ASA have a 9% probability of PPM implantation within 30 days after ASA. In long-term follow-up, patients with PPM had similar long-term survival and New York Heart Association functional class but lower LV outflow gradient, a more pronounced LV outflow gradient decrease, a lower LV ejection fraction, and a lower likelihood of reintervention compared with patients without PPM. © 2022 American College of Cardiology Foundation
Ключевые слова: ALCOHOL SEPTAL ABLATION
PERMANENT PACEMAKER
PROGNOSIS
ABLATION TECHNIQUES
ATRIOVENTRICULAR BLOCK
CARDIOMYOPATHY, HYPERTROPHIC
ETHANOL
HEART SEPTUM
HUMANS
PACEMAKER, ARTIFICIAL
RETROSPECTIVE STUDIES
TREATMENT OUTCOME
ALCOHOL
ADULT
ALCOHOL SEPTAL ABLATION
ALL CAUSE MORTALITY
ARTICLE
ATRIOVENTRICULAR BLOCK
CLINICAL EXAMINATION
COHORT ANALYSIS
CONTROLLED STUDY
FEMALE
FOLLOW UP
HEART BUNDLE BRANCH BLOCK
HEART LEFT VENTRICLE EJECTION FRACTION
HUMAN
HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY
INTERVENTRICULAR SEPTUM
MAJOR CLINICAL STUDY
MALE
MIDDLE AGED
MUSCLE RESECTION
NEW YORK HEART ASSOCIATION CLASS
OUTCOME ASSESSMENT
PACEMAKER IMPLANTATION
PROPENSITY SCORE
SHARED DECISION MAKING
SUDDEN CARDIAC DEATH
ABLATION THERAPY
ADVERSE EVENT
ARTIFICIAL HEART PACEMAKER
ATRIOVENTRICULAR BLOCK
DIAGNOSTIC IMAGING
HEART SEPTUM
HYPERTROPHIC CARDIOMYOPATHY
RETROSPECTIVE STUDY
TREATMENT OUTCOME
URI: http://elar.urfu.ru/handle/10995/132486
Условия доступа: info:eu-repo/semantics/openAccess
publisher-specific-oa
Идентификатор SCOPUS: 85138367372
Идентификатор WOS: 000879070600005
Идентификатор PURE: f36e2b64-320b-4856-a0a9-7b2afe3189f3
30981587
ISSN: 1936-8798
DOI: 10.1016/j.jcin.2022.06.034
Располагается в коллекциях:Научные публикации ученых УрФУ, проиндексированные в SCOPUS и WoS CC

Файлы этого ресурса:
Файл Описание РазмерФормат 
2-s2.0-85138367372.pdf543,51 kBAdobe PDFПросмотреть/Открыть


Все ресурсы в архиве электронных ресурсов защищены авторским правом, все права сохранены.